UKLS Trial Meta-Analysis Confirms that Low Dose CT Screening for Lung Cancer Reduces Mortality
DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.
- DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.
- Previous studies, such as the National Lung Cancer Screening Trial and The NELSON LDCT screening trial, provided evidence of a statistically significant reduction (20%, 24% respectively) in lung cancer mortality.
- Results from these nine randomized controlled trials were included in the meta-analysis indicated a significant reduction in lung cancer mortality.
- The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.